| Q36692259 | 5,7-Dihydroxyflavone Enhances the Apoptosis-Inducing Potential of TRAIL in Human Tumor Cells via Regulation of Apoptosis-Related Proteins |
| Q34722539 | APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo |
| Q38960128 | Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors |
| Q64987315 | Engineered human mesenchymal stem cells for neuroblastoma therapeutics. |
| Q34474267 | Evaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomas |
| Q33828114 | Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety. |
| Q35783593 | Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFα)-induced apoptosis through SIRT1 inhibition. |
| Q36512525 | Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors |
| Q37585453 | Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma |
| Q34132999 | Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo |
| Q37403279 | Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity |
| Q37356520 | Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide |